EyePoint Pharmaceuticals has been granted a patent for compounds that can activate Tie-2 and inhibit HPTP-beta, providing effective therapy for eye conditions associated with angiogenesis such as intraocular pressure, ocular hypertension, and glaucoma. The patent claims a method for reducing intraocular pressure in humans by administering a therapeutically-effective amount of a Tie-2 activator, resulting in a reduction of intraocular pressure by 0.1 mmHg to 9 mmHg compared to no administration. GlobalData’s report on EyePoint Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on EyePoint Pharmaceuticals, NSAID cancer drugs was a key innovation area identified from patents. EyePoint Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for a method to reduce intraocular pressure
A recently granted patent (Publication Number: US11666558B2) describes a method for reducing intraocular pressure in individuals with elevated intraocular pressure, particularly those with glaucoma. The method involves administering a therapeutically-effective amount of a Tie-2 activator to the subject. The administration of the Tie-2 activator results in a reduction in intraocular pressure ranging from about 0.1 mmHg to about 9 mmHg compared to the absence of administration.
The method specified in the patent claims can be applied to human subjects expressing Ang-1 and Ang-2. The Tie-2 activator is a compound that conforms to a specific formula. The administration of the Tie-2 activator can be done directly to the eye of the subject (intravitreal administration). The reduction in intraocular pressure is expected to occur within 28 days of administration, with a minimum reduction of about 2 mmHg compared to the absence of administration.
The patent also highlights that the method is particularly applicable to individuals with glaucoma, where the elevated intraocular pressure is associated with the condition. The Tie-2 activator compound works by stabilizing the vasculature associated with a trabecular meshwork in the subject, which contributes to the reduction in intraocular pressure.
The therapeutically-effective amount of the Tie-2 activator to be administered ranges from about 1 mg to about 300 mg, or alternatively, from about 0.5 mg to about 30 mg. The method is also applicable to individuals with ocular hypertension, where the elevated intraocular pressure is associated with glaucoma.
In summary, the granted patent describes a method for reducing intraocular pressure in individuals with elevated intraocular pressure, particularly those with glaucoma. The method involves administering a therapeutically-effective amount of a Tie-2 activator, which results in a reduction in intraocular pressure ranging from about 0.1 mmHg to about 9 mmHg compared to the absence of administration. The Tie-2 activator works by stabilizing the vasculature associated with a trabecular meshwork in the subject. The method is applicable to human subjects expressing Ang-1 and Ang-2 and can be administered intravitreally.
To know more about GlobalData’s detailed insights on EyePoint Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
